PL2245463T3 - Sposób diagnozowania - Google Patents

Sposób diagnozowania

Info

Publication number
PL2245463T3
PL2245463T3 PL09709860T PL09709860T PL2245463T3 PL 2245463 T3 PL2245463 T3 PL 2245463T3 PL 09709860 T PL09709860 T PL 09709860T PL 09709860 T PL09709860 T PL 09709860T PL 2245463 T3 PL2245463 T3 PL 2245463T3
Authority
PL
Poland
Prior art keywords
diagnostic method
diagnostic
Prior art date
Application number
PL09709860T
Other languages
English (en)
Inventor
Lisbeth Johnsen
Kaj Blennow
Tormod Fladby
Original Assignee
Inven2 As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inven2 As filed Critical Inven2 As
Publication of PL2245463T3 publication Critical patent/PL2245463T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
PL09709860T 2008-02-15 2009-02-13 Sposób diagnozowania PL2245463T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0802851.6A GB0802851D0 (en) 2008-02-15 2008-02-15 Diagnostic method
EP09709860.2A EP2245463B1 (en) 2008-02-15 2009-02-13 Diagnostic method
PCT/EP2009/001210 WO2009100953A2 (en) 2008-02-15 2009-02-13 Diagnostic method

Publications (1)

Publication Number Publication Date
PL2245463T3 true PL2245463T3 (pl) 2014-06-30

Family

ID=39271801

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09709860T PL2245463T3 (pl) 2008-02-15 2009-02-13 Sposób diagnozowania

Country Status (7)

Country Link
US (4) US9625474B2 (pl)
EP (1) EP2245463B1 (pl)
DK (1) DK2245463T3 (pl)
ES (1) ES2455216T3 (pl)
GB (1) GB0802851D0 (pl)
PL (1) PL2245463T3 (pl)
WO (1) WO2009100953A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071359A1 (en) * 2012-11-05 2014-05-08 Msdx, Inc. Detection of neurological diseases via measurement of neuromelanin in recirculating phagocytes
GB0802851D0 (en) 2008-02-15 2008-03-26 Medinnova As Diagnostic method
AU2011336895A1 (en) * 2010-11-24 2013-06-06 Elan Pharmaceuticals, Inc. Phagocytic activity as a marker of synucleinopathic disease
EP2495567A1 (en) * 2011-03-04 2012-09-05 Erasmus University Medical Center Rotterdam Methods and means for monitoring disruption of tissue homeostasis in the total body
EP3262070A4 (en) * 2015-02-24 2018-07-25 Rpeptide, LLC Anti-amyloid-beta antibodies
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JP7194926B2 (ja) * 2018-06-28 2022-12-23 東亞合成株式会社 ３大神経変性疾患の診断補助方法
WO2022189463A1 (en) 2021-03-08 2022-09-15 Akershus Universitetssykehus Hf Clearance assay

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213067T1 (de) 1996-03-06 2002-02-15 Manfred Hartwig Differentialdianostisches verfahren zum nachweis verschiedener stadien der alzheimer-krankheit
US7687231B2 (en) * 2006-01-30 2010-03-30 Yamasa Corporation Method for determining degree of negative effect of macrophages on vertebrate
GB0802851D0 (en) 2008-02-15 2008-03-26 Medinnova As Diagnostic method
US20110263450A1 (en) 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers

Also Published As

Publication number Publication date
US20110124010A1 (en) 2011-05-26
EP2245463B1 (en) 2014-01-01
US9625474B2 (en) 2017-04-18
US20210109114A1 (en) 2021-04-15
WO2009100953A2 (en) 2009-08-20
GB0802851D0 (en) 2008-03-26
EP2245463A2 (en) 2010-11-03
US20180067127A9 (en) 2018-03-08
US20170307632A1 (en) 2017-10-26
DK2245463T3 (da) 2014-04-07
ES2455216T3 (es) 2014-04-15
WO2009100953A3 (en) 2009-11-05
US10281477B2 (en) 2019-05-07
US20190204343A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
GB0820927D0 (en) Method
GB0818093D0 (en) Method
GB0803107D0 (en) Method
GB0810418D0 (en) Method
EP2310850A4 (en) DIAGNOSTIC PROCEDURE
GB0807409D0 (en) Method
GB0815428D0 (en) Method
GB0813599D0 (en) Method
GB0807410D0 (en) Method
GB0804981D0 (en) Method
PL2245463T3 (pl) Sposób diagnozowania
GB0804690D0 (en) Method
GB0809404D0 (en) Method
EP2321435A4 (en) WIEDERAUFKOHLUNGSVERFAHREN
GB0812559D0 (en) Method
GB0805862D0 (en) Method
GB0813494D0 (en) Method
GB0812102D0 (en) Method
GB0806186D0 (en) Method
GB0718748D0 (en) Diagnostic method
GB0811166D0 (en) Method
GB0810116D0 (en) Method
GB0816867D0 (en) Method
GB0812497D0 (en) Method
GB0803833D0 (en) Diagnostic methods